Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

10/08/2026 Eastern Time in USA The Dow Jones Industrial Average dropped by 0.11%, closing at 53975.98 points; the Nasdaq Composite dropped by 0.32%, closing at 26605.36 points; the S&P 500 Index dropped by 0.06%, closing at 7753.11 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

The Top 10 Daily Gainers in the USA market are listed as follows:

Bowman Consulting Group, Ltd.: Overnight gain 55.8%, Surges Amid Buyout Offer, Strong Earnings Beat, and Major Government Contract Win

**Bowman Consulting Group, Ltd. – Corporate Profile** Bowman Consulting Group, Ltd. was originally incorporated in the Commonwealth of Virginia on June 5, 1995, and subsequently completed its redomiciliation to the State of Delaware on November 13, 2020. The Company is a professional services firm dedicated to delivering innovative solutions to clients operating within the built environment sector. With a client base exceeding 2,200 entities, Bowman offers a comprehensive suite of services spanning planning, engineering, construction management, commissioning, environmental consulting, geospatial services, surveying, land acquisition, and technology services.

Bowman Consulting Group, Ltd.(BWMN.US) Surges 55.8% on Triple Catalysts** Shares of Bowman Consulting Group, Ltd. (BWMN) soared 55.8% in a single session, driven by three simultaneous positive developments. Private equity firm Bernhard Capital Partners announced a definitive agreement to acquire and take BWMN private at $43.00 per share in cash, valuing the company at approximately $1 billion — representing a roughly 58% premium to the prior closing price. The transaction has received unanimous Board approval and is expected to close between Q4 2026 and Q1 2027. Concurrently, Bowman Consulting Group, Ltd. (BWMN) reported Q2 adjusted EPS of $0.62, beating consensus estimates by 87.88%, while revenue reached $146.1 million, up 19.69% year-over-year and exceeding expectations by 5.40%. Additionally, the U.S. Department of Agriculture awarded Bowman Consulting Group, Ltd. (BWMN) an $11.2 million multi-state aerial data acquisition contract, further bolstering investor sentiment.

Varex Imaging Corporation: Overnight gain 48.8%, Surges Amid Teledyne Acquisition Offer and Strong Earnings Beat

**Varex Imaging Corporation: Company Profile** Varex Imaging Corporation, incorporated in the State of Delaware on July 18, 2016, is a leading innovator and manufacturer specializing in X-ray tubes, digital detectors, linear accelerators, and image processing software solutions. The Company's comprehensive product portfolio serves a broad spectrum of applications across the medical diagnostic imaging sector, encompassing general radiography, computed tomography (CT), C-arm, angiography, fluoroscopy, mammography, and dental imaging modalities. In addition, the Company extends its capabilities to industrial security inspection and analytical measurement applications within the manufacturing sector. Numerous original equipment manufacturers (OEMs) worldwide integrate Varex Imaging's X-ray imaging components into their systems for detection, diagnostics, and security purposes.

Varex Imaging Corporation(VREX.US) Surges 48.8% Following Teledyne Acquisition Announcement** Shares of Varex Imaging Corporation (VREX) posted a remarkable single-session gain of 48.8%, driven by a dual catalyst of a premium acquisition offer and robust quarterly earnings. Teledyne Technologies announced a definitive agreement to acquire all outstanding common shares of Varex Imaging Corporation (VREX) at $18.90 per share in cash, valuing the transaction at approximately $1.1 billion. The deal has received unanimous approval from both companies' boards of directors. Compounding the bullish momentum, Varex Imaging Corporation (VREX) reported third-quarter adjusted EPS of $0.31, significantly exceeding consensus estimates by 47.62% and representing a 72.22% year-over-year increase. Quarterly revenue reached $210.5 million, up 3.69% year-over-year, reflecting solid fundamental performance. The combination of the high-premium takeover bid and strong earnings results has driven Varex Imaging Corporation's (VREX) year-to-date cumulative gains to 58.5%.

MarineMax, Inc.: Overnight gain 46.1%, Surges Amid BlackRock-Backed Safe Harbor All-Cash Acquisition at Significant Premium

**MarineMax, Inc. – Company Overview** MarineMax, Inc., incorporated in January 1998, stands as the world's largest recreational boat and yacht retailer by scale. The Company's core business operations encompass the retail sale of new and pre-owned recreational boats, yachts, and a comprehensive range of marine-related products and services. MarineMax currently operates a network of 81 retail locations across 21 states throughout the United States. The Company's product portfolio includes recreational boats, engines, trailers, parts, and accessories. In addition to its retail offerings, MarineMax provides an integrated suite of value-added services, including boat financing arrangements, insurance products, and extended service contracts. The Company further engages in boat maintenance and repair services, yacht brokerage sales, as well as slip and storage services available on an as-needed basis.

MarineMax, Inc.(HZO.US) Shares Surge on Acquisition Announcement** Shares of MarineMax, Inc. (HZO) rallied sharply following the announcement that Safe Harbor, a subsidiary of BlackRock Infrastructure, has agreed to acquire MarineMax, Inc. (HZO) in an all-cash transaction valued at approximately $1.5 billion, or $53.00 per share. The offer represents a premium of approximately 96% to the company's prior closing price of $27.03 and roughly 110% to the 90-trading-day volume-weighted average price, directly catalyzing a significant re-rating of the stock. The transaction followed a competitive strategic review process, which attracted participation from institutional bidders including Blackstone Group. The deal was unanimously approved by MarineMax, Inc. (HZO)'s Board of Directors, which has recommended shareholders vote in favor. The transaction carries no financing contingency and is expected to close before year-end 2026, upon which MarineMax, Inc. (HZO) will be delisted from the New York Stock Exchange. Arbitrage capital continues to drive the share price toward the $53.00 acquisition price.

Jin Medical International Ltd. Class A: Overnight gain 35.8%, Surges Amid Interim Financial Results Release, Driven by Improved Margins and Strong Liquidity

Jin Medical International Ltd. Class A(ZJYL.US) Surges Amid Unaudited Financial Results Release** Shares of Jin Medical International Ltd. Class A (ZJYL) experienced a significant upward movement, with the release of its unaudited interim financial results for the six months ended March 31 serving as the primary catalyst. Despite reporting a 9.7% year-over-year revenue decline to $8.9 million, the company demonstrated improving operational efficiency, as gross margin expanded from 24.3% to 26.9%. Wheelchair component sales rose 9.9%, while R&D expenditures surged 33.4% to $0.9 million, signaling continued investment in innovation. The company maintained robust liquidity, holding $9.1 million in cash alongside $21 million in short-term investments. Notably, Jin Medical International Ltd. Class A (ZJYL)'s market capitalization of approximately $15.19 million stood well below its combined cash and short-term investment holdings, presenting a compelling valuation discount. The confluence of positive financial indicators and apparent undervaluation triggered an exceptional market response, with trading volume reaching over 327 times the daily average.

Standard Nuclear, Inc. Class A: Overnight gain 35.7%, Surges Amid Unanimous Buy Ratings From Top Wall Street Banks on Nuclear Fuel Outlook

**Standard Nuclear, Inc. Class A** Standard Nuclear, Inc., incorporated on July 15, 2024, is an advanced nuclear fuel company specializing in uranium conversion and the research and development of high-specification nuclear fuel products. The Company's core business is centered on the scaled manufacturing of Tristructural Isotropic (TRISO) fuel — a critical high-durability fuel designed for advanced nuclear reactors — which carries significant strategic value within the nuclear energy supply chain. By integrating its proprietary technological capabilities with operational resources, the Company is committed to accelerating the development of a domestic TRISO fuel supply infrastructure while providing long-term support for the advancement of the United States' advanced nuclear energy industry.

Standard Nuclear, Inc. Class A(STDN.US) Surges 35.7% on Broad Wall Street Coverage Initiation** Shares of Standard Nuclear, Inc. Class A (STDN) posted a remarkable single-session gain of 35.7%, closing at $8.44, driven by a confluence of bullish catalysts. Notably, six premier Wall Street institutions — Stifel, Evercore ISI, UBS Group, Barclays, and BofA Securities — simultaneously initiated coverage on the stock, unanimously assigning positive ratings including Buy, Outperform, and Overweight designations. Price targets ranged from $14 to $17 per share, representing a premium of up to approximately 100% over the closing price. The rare convergence of institutional consensus generated significant market resonance. Further supporting the rally, Standard Nuclear, Inc. Class A (STDN)'s strategic focus on TRISO nuclear fuel production aligns with the broader nuclear energy renaissance theme, while the stock's year-to-date decline of 23.7% had accumulated considerable valuation recovery potential, collectively catalyzing the sharp upside move.

AbCellera Biologics, Inc.: Overnight gain 34.8%, Surges Amid Positive Clinical Trial Results and Analyst Target Price Upgrades

**AbCellera Biologics Inc. Incorporated Under British Columbia Business Corporations Act, Focused on Accelerating Antibody Drug Discovery** AbCellera Biologics Inc. was incorporated on November 8, 2012, under the Business Corporations Act of British Columbia. The Company operates within the medical research and development sector, leveraging an integrated suite of sophisticated technologies designed to accelerate the discovery of antibody-based therapeutics with greater efficiency and at reduced cost. Since its inception, AbCellera has maintained a sustained commitment to research and development activities, directed toward advancing existing partnered programs while simultaneously supporting the continued development of its proprietary platform capabilities for future applications.

AbCellera Biologics, Inc.(ABCL.US) Surges 34.8% on Positive Phase 2 Clinical Data and Analyst Upgrades** Shares of AbCellera Biologics, Inc. (ABCL) posted a remarkable single-session gain of 34.8%, bringing year-to-date appreciation to 173.1%, driven by a confluence of positive catalysts. The company announced that ABCL635, its investigational asset, successfully met the primary efficacy endpoints in the Phase 2 portion of its Phase 1/2 clinical trial. At Week 4 following a single administration, ABCL635 demonstrated statistically significant reductions in both the frequency and severity of moderate-to-severe vasomotor symptoms (hot flashes) versus placebo, while meaningfully improving sleep quality and Patient Global Impression of Change (PGI-C) scores, with a favorable tolerability profile. The compound is regarded as having **best-in-class** potential. Adding further momentum, analysts at Cantor Fitzgerald and Stifel subsequently raised their price targets to **$12** and **$9**, respectively, amplifying the bullish sentiment.

Silence Therapeutics PLC Sponsored ADR: Overnight gain 29.1%, Surges Amid Strong Earnings Beat and Positive Divesiran Trial Data Expectations

Silence Therapeutics Plc, incorporated on November 18, 1994, is a publicly listed limited company registered under the laws of England and Wales. The company is a biopharmaceutical enterprise specializing in the research and development of novel molecular entities, including short interfering ribonucleic acid (siRNA) therapeutics, designed to selectively silence the expression of specific target genes with the objective of addressing diseases characterized by significant unmet medical needs.

Silence Therapeutics PLC Sponsored ADR(SLN.US) Surges 29.1% on Clinical Catalyst and Earnings Beat** Shares of Silence Therapeutics PLC Sponsored ADR (SLN) rallied 29.1% in a single session, driven by a powerful confluence of clinical and financial catalysts. The company announced a dedicated conference call to present top-line results from the Phase 2 SANRECO trial evaluating its lead asset divesiran in polycythemia vera, with the anticipated clinical data disclosure significantly boosting market sentiment. Compounding the momentum, Silence Therapeutics reported Q2 EPS of $(0.09), substantially outperforming the consensus analyst estimate of $(0.15) by approximately 40%, while representing an 84.21% improvement compared to the $(0.57) loss recorded in the prior-year period. The dual tailwinds of promising clinical progress and a robust earnings surprise have propelled SLN's year-to-date cumulative gains to an impressive 153.8%.

Innate Pharma SA: Overnight gain 28.3%, Surges Amid Clinical Trial Progress and Immuno-Oncology Sector Momentum

**Innate Pharma S.A.: A Clinical-Stage Biotechnology Pioneer in Cancer Immunotherapy** Incorporated on September 23, 1999, Innate Pharma S.A. is a clinical-stage biotechnology company specializing in oncology immunotherapy. Leveraging its core technological expertise in antibody engineering and innovative target identification, the Company is dedicated to the research and development of next-generation, differentiated antibody-based therapeutics, with the aim of delivering transformative treatment options for patients with cancer.

Innate Pharma SA(IPHA.US) Surges 28.3% Overnight Amid Multiple Catalysts** Shares of Innate Pharma SA (IPHA), a clinical-stage biopharmaceutical company specializing in cancer immunotherapy, soared 28.3% overnight, bringing year-to-date gains to 26.9%. The sharp single-session rally is attributed to a confluence of driving factors characteristic of high-momentum biotech names. Catalyst events — including clinical trial data readouts, pipeline advancement milestones, or regulatory approval progress — are widely regarded as the primary drivers behind such significant intraday moves. Concurrently, the immuno-oncology sector continues to attract sustained institutional interest, underpinning broader sector momentum. Innate Pharma SA's (IPHA) differentiated capabilities in antibody engineering and innovative target identification, combined with a market reassessment of the pipeline value of its next-generation antibody therapies, have collectively reinforced the stock's upward trajectory throughout the year.

National Energy Services Reunited Corp.: Overnight gain 23.3%, Surges Amid Major Kuwait Contracts, Strong Q2 Earnings Beat, and Strategic Partnership Wins

**National Energy Services Reunited Corp. Overview** National Energy Services Reunited Corp. (NESR), incorporated on January 23, 2017, stands as one of the largest oilfield services providers operating across the Middle East and North Africa (MENA) region. The Company generates revenues through two principal business segments, each designed to address critical phases of hydrocarbon extraction and reservoir development. The first segment, **Production Services**, encompasses a comprehensive suite of offerings — including cementing, coiled tubing, filtration, completion, stimulation, pumping, and nitrogen services — all aimed at enabling clients to maximize reservoir productivity and optimize hydrocarbon recovery. The second segment, **Drilling and Evaluation Services**, delivers a broad range of technical capabilities, including downhole tools, directional drilling, fishing tools, testing services, wireline, slickline, fluids, and rig services, providing clients with efficient and reliable access to target reservoirs. Geographically, NESR maintains a significant operational footprint across key MENA markets, with established presences in Saudi Arabia, Oman, Qatar, Iraq, Algeria, and Kuwait, reinforcing its strategic positioning as a leading integrated oilfield services provider in one of the world's most prolific hydrocarbon-producing regions.

National Energy Services Reunited Corp.(NESR.US) Surges 23.3% on Record Contracts and Blowout Earnings** Shares of National Energy Services Reunited Corp. (NESR) soared 23.3% in a single session, bringing year-to-date gains to an impressive 128.5%, driven by a confluence of powerful catalysts. The company secured multiple contracts in Kuwait totaling **$300 million over five years**, spanning production services and drilling evaluation, alongside a Master Technology Agreement (MTA) advancing its open technology platform across the Middle East. NESR's Q2 results significantly exceeded expectations, with revenue reaching **$520.75 million**, surpassing estimates by 16.51% and surging 59.07% year-over-year. Adjusted EPS came in at **$0.44**, representing a robust 109.52% year-over-year increase. Additionally, NESR was named a founding member of the Ahmadi Innovation Valley and awarded its first joint operating contract with Kuwait Oil Company (KOC), materially strengthening its strategic positioning in the region.

Nutex Health Inc: Overnight gain 21.9%, Surges Amid Massive EPS Beat, Driven by Profitability Turnaround and Cost Discipline

**Nutex Health Inc. – Company Overview** Nutex Health Inc. was incorporated in the State of Delaware on April 13, 2000, and is headquartered in Houston, Texas, United States. The Company operates as a physician-led healthcare services and operations enterprise, conducting business across three principal segments: the Hospital Division, which oversees the management of micro-hospitals and specialized medical facilities; the Population Health Management Division, which coordinates and administers networks of healthcare providers; and the Real Estate Division.

Nutex Health Inc(NUTX.US) Surges on Robust Earnings Beat** Shares of Nutex Health Inc (NUTX) rallied sharply, driven by a standout second-quarter earnings performance. The physician-led healthcare services operator reported Q2 EPS of $9.38, dramatically surpassing analyst consensus estimates of $4.95 by 89.49%, marking a fundamental turnaround from a loss of $2.95 per share in the prior-year period — a remarkable year-over-year improvement of 417.97%. While quarterly revenue of $210.75 million fell marginally short of expectations by 1.99% and declined 13.62% year-over-year, markets responded favorably to the significant profitability expansion. The combination of revenue contraction alongside substantial earnings growth signals meaningful progress in cost discipline and strategic focus on higher-margin business segments. The decisive earnings outperformance reversed market sentiment, directly catalyzing a single-session gain of 21.9% in NUTX shares, bringing year-to-date appreciation to 20.0%.

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team. Risk and Disclaimer: The content provided above is solely for informational purposes and does not represent the views or positions of Sahm Platform. While we strive for accuracy, we cannot guarantee the authenticity or completeness of the information contained in the provided content. We strongly recommend that investors consult with a qualified investment advisor when deemed necessary. Sahm Platform neither provides investment advice nor makes any representations or warranties concerning the accuracy, reliability, or completeness of the information in the content provided above. By using Sahm Platform, you acknowledge that you have read, understood, and agreed to the terms set forth in this disclaimer.